Coherus Oncology Completes $47 Million Public Offering
CHRS has more than doubled off its 52-week low of $0.71.
Summary
Coherus Oncology completed its public offering, securing $47.0 million in net proceeds from the sale of 28.6 million shares at $1.75 each, bolstering its financial resources.
Key Events · Financing and Capital Events · CHRS
-
Offering Completed
Coherus Oncology finalized the sale and issuance of 28.6 million shares of common stock on February 17, 2026.
-
Net Proceeds Received
The company received approximately $47.0 million in net proceeds from the offering, after deducting underwriting discounts and commissions.
-
Pricing Details
Shares were offered to the public at $1.75 per share, with underwriters purchasing at $1.645 per share.
-
Lock-Up Agreements
Directors, executive officers, and certain stockholders entered into 60-day lock-up agreements restricting stock sales, subject to customary exceptions.
Analysis · CHRS · Life Sciences
Coherus Oncology, Inc. announced the completion of its previously disclosed underwritten public offering, raising approximately $47.0 million in net proceeds. This capital raise, which involved the sale of 28.6 million shares at $1.75 per share, provides crucial funding for the company's operations and strategic initiatives. While the offering is significantly dilutive, the successful completion of the capital raise helps to strengthen the company's financial position and extend its operational runway.
At the time of this filing, CHRS was trading at $1.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $194.6M. The 52-week trading range was $0.71 to $2.62. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.